New COVID-19 Vaccine Codes: April Update

The CPT Editorial Panel (the Panel) has approved a vaccine product code (91310) and its associated vaccine administration code (0104A) for the new Sanofi Pasteur vaccine product to address severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) in adult patients aged 18 years and older. In addition to the new Sanofi Pasteur codes, the Panel also approved a new Pfizer booster dose vaccine administration code (0074A) that is to be reported with vaccine product code 91307 when a booster dose of the Pfizer vaccine is administered to a pediatric patient aged 5 through 11 years. These three codes will become effective upon receiving emergency use authorization (EUA) from the Food and Drug Administration (FDA).

In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated administration codes, the American Medical Association (AMA) established a website (https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes) that features timely updates of the Panel’s actions. The last COVID-19 update was in the CPT® Assistant Special Edition: March Update (2022) in which the Moderna vaccine product (91309) and vaccine administration (0094A) codes for adult patients ages 18 years and older were discussed.

This issue of CPT® Assistant Special Edition introduces and provides guidance on the appropriate use of the new Sanofi Pasteur vaccine product booster dose code (91310) and its associated vaccine administration code (0104A) as well as the new Pfizer booster dose administration code (0074A).

**Immunization Administration for Vaccines/Toxoids**

#0074A  Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion; booster dose

► (Report 0104A for the administration of vaccine 91310)

Vaccines, Toxoids

#●91310 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use

► (Report 91310 with administration code 0104A)

Code 91310 describes Sanofi Pasteur’s COVID-19 vaccine product for adult patients aged 18 years and older. This vaccine uses a 5 mcg/0.5 mL dosage concentration, and it will be used only as a booster dose for patients who have already completed a primary series of any approved COVID-19 vaccine (Pfizer, Moderna, or Janssen [Johnson & Johnson]). Code 0104A is the new vaccine booster dose administration code to be reported with Sanofi Pasteur’s COVID-19 vaccine product (91310). Note that there will be no primary series available for the Sanofi COVID-19 vaccine.

Code 0074A is the new vaccine booster dose administration code to be reported with Pfizer’s already established vaccine product code (91307) for patients aged 5 through 11 years of age. Please refer to the guidance provided by the Centers for Disease Control and Prevention (CDC) regarding the dosing intervals for these booster doses.

As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit and should not be reported separately. The physician or other qualified health care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given patient. More information on current guidance from the CDC regarding which patients should receive a COVID-19 vaccine booster dose as well as dosing intervals is available at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html.

Note that vaccine administration code 0104A is only intended to be reported with vaccine product code 91310 and administration code 0074A is only intended to be reported with vaccine product code 91307. Parenthetical notes have been added following the administration and product codes to clarify the appropriate use of these new codes.

To accommodate the new coding structure, Appendix Q was added to the CPT code set. Appendix Q details the vaccine codes, their associated vaccine administration code(s), the vaccine manufacturers and names, the National Drug Code (NDC) labeler product ID, and dosing intervals. The new Sanofi Pasteur booster dose vaccine product (91310) and vaccine administration (0104A) codes as well as the Pfizer booster dose administration code (0074A) have also been added to Appendix Q.


The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

Clinical Example (0074A)
A parent/guardian seeks booster immunization for their 5-year-old child who was previously immunized with a primary series against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The parent/guardian is offered and accepts, on the child’s behalf, an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (0074A)
The physician or other qualified health care professional (QHP) reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. The parent/guardian is counseled on the
benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the booster dose of the COVID-19 vaccine by intramuscular injection in the upper arm. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.

**Clinical Example (91310)**

A 33-year-old individual who was previously immunized with a primary series seeks booster immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

**Description of Procedure (91310)**

The physician or other QHP determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the booster vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

**Clinical Example (0104A)**

A 33-year-old individual who was previously immunized with a primary series seeks booster immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

**Description of Procedure (0104A)**

The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the booster dose of the COVID-19 vaccine by intramuscular injection in the upper arm. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.